Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis. - Wikidata - awgldk - TriplyDB

Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis.

Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis.

http://www.wikidata.org/entity/Q38163071

about

Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes Bringing patient centricity to diabetes medication access in Canada Comparative effectiveness of sodium-glucose co-transporter 2 inhibitors for controlling hyperglycaemia in patients with type 2 diabetes: protocol for a systematic review and network meta-analysis Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis A Systematic Review of Methods for Handling Missing Variance Data in Meta-Analyses of Interventions in Type 2 Diabetes Mellitus.Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.Dapagliflozin for the treatment of type 2 diabetes: a review of the literature Dapagliflozin in patients with type 2 diabetes mellitus.The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials.Glycaemic control efficacy of oral antidiabetic drugs in treating type 2 diabetes: a protocol for network meta-analysis.The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Increases Circulating Zinc-Α2-Glycoprotein Levels in Patients with Type 2 Diabetes.Paradoxical insights into whole body metabolic adaptations following SGLT2 inhibition.Liraglutide Versus SGLT-2 Inhibitors in People with Type 2 Diabetes: A Network Meta-Analysis Sodium glucose co-transporter 2 (SGLT2) inhibitors: new among antidiabetic drugs.Dapagliflozin: a review of its use in patients with type 2 diabetes.The effect of SGLT2 inhibitors on cardiovascular events and renal function.SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment.Emerging use of combination therapies for the management of type 2 diabetes - focus on saxagliptin and dapagliflozin.The Role of SGLT-2 Inhibitors as Part of Optimal Medical Therapy in Improving Cardiovascular Outcomes in Patients with Diabetes and Coronary Artery Disease.A systematic review and mixed treatment comparison of monotherapy in early Parkinson's disease: implications for Latin America.The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -/- mice fed a western diet.Role of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus.Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.Pharmacokinetic and pharmacodynamic drug evaluation of tofogliflozin for the treatment of type 2 diabetes.Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes.Durability of response to dapagliflozin: a review of long-term efficacy and safety.Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study.Comparison between sodium-glucose cotransporter 2 inhibitors and pioglitazone as additions to insulin therapy in type 2 diabetes patients: A systematic review with an indirect comparison meta-analysis.Dapagliflozin therapy in type-2 diabetes: current knowledge and future perspectives.Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes.

P2860

Q26782225-4CFA17AB-09B5-4D5C-8829-DB98F8366EE4 Q26864336-3F394B0A-9FC2-41D6-9864-EA773F777078 Q28067085-262EBFD3-A261-45B5-B1DE-BF4DA5ACA127 Q28074573-3ED76A15-2706-4E0B-BD64-B08AC919738A Q28553482-4932185B-2046-4E3D-A9BA-7B1952DCBE5C Q31137238-42A320DD-F507-4F19-AD48-52D0A0B39CD8 Q34457919-1E0051B1-4BBF-4E58-8AF4-4A29E21B1144 Q34710819-27334E9F-6ACD-487B-8A17-FED42293AE2D Q35064363-2A7C5A0F-2910-430F-87B6-C16A7E8FE5B1 Q35141884-CECDECCD-45DB-4E6A-A71B-BA2190AF724C Q35179679-729978A7-DDCE-4F5D-B2C1-75A32EFE36CB Q35260544-19655AC4-FE05-4A19-9101-A389F7C691CC Q35528766-7EA6B50E-ED43-4BB9-8FA8-E82CAC2DC766 Q35833876-CAB99725-24DA-4201-A696-024B22211330 Q37244327-2F912058-DDEF-47DC-9290-E6FC26B85C25 Q37524351-9CE9D85D-CAB8-4A1A-8E04-26F1D6DBE84B Q37639297-C8ADD06C-1E28-47CB-9DB9-70BD46F311C5 Q38211597-6C27F5DD-11FD-4575-8E04-5E711E879027 Q38267346-20877D1B-6577-4273-8101-21BFD760C3BF Q38614488-AE46ACC3-D617-481B-A161-A2D137769483 Q38619164-625578C1-B129-4EDB-9E54-DB20BEABF35D Q38645792-AF8BE651-FCCF-4499-B426-7E28CF25B25A Q38679997-943BBE03-1DF7-49C4-A6AE-71B68D186DC9 Q38687026-5F32DBA1-2681-4FF2-8AA9-EE5011CC4B72 Q38730067-A0E298C7-0E20-43FF-BB21-93061AC305FA Q38796262-3DA292B3-1C96-43A1-A33E-97D817E38C66 Q38802437-AD43999F-9BEA-4E22-85A2-817CA59DE86C Q38936746-3D0A773C-9F2A-4577-BD36-7E6023F86075 Q39170860-616831A7-BAB8-4804-B56C-7FC2D9282C7D Q39430445-0AB361F4-9DA8-41E8-9238-498BBB604CEA Q39738725-D9F40780-FEA5-4D08-96B3-D5499D6CD2BE Q41678361-B81A8AEF-F470-4FE3-944F-E6E649DDBF29 Q48160690-94E6C94A-0088-4534-BB42-9F881001CDE0 Q48664757-C6C55A50-7F2C-4779-8072-831D1C60B447 Q49963693-F766C421-0211-4E1E-A461-5E65404342D4

P2860

Dapagliflozin compared with other oral anti-diabetes treatments when added to metformin monotherapy: a systematic review and network meta-analysis.

http://www.wikidata.org/entity/Q38163071

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Dapagliflozin compared with ot ...... iew and network meta-analysis.

@en

type

label

Dapagliflozin compared with ot ...... iew and network meta-analysis.

@en

prefLabel

Dapagliflozin compared with ot ...... iew and network meta-analysis.

@en

P1433

Q38163071-75840B32-AA01-4829-88D2-3A907D80516C

P1476

Q38163071-AD03C0A7-436D-4406-9C88-E244EB08EE31

P2093

Q38163071-02819A9C-9C92-4728-8F29-C96998773DE0

Q38163071-1A5935D5-6C40-4D61-8CB0-CF57719B01EB

Q38163071-4F371590-7191-4BE0-93F4-D534097E7FC9

Q38163071-5E37AC10-8B58-444C-9429-70E1CEFBCA5D

Q38163071-6981A9F7-C5B5-4A4B-A701-F93EE16252C7

Q38163071-F52AA58E-A9B3-4A2D-9721-EE29EA0FFC5F

Q38163071-F79361D9-A107-4213-9F13-25DBAA92B37B

P2860

Q38163071-0178D5B3-F9A0-4106-A91B-EBF5B26E8C13

Q38163071-037F2DB0-2539-4042-966A-BC39535A983F

Q38163071-164AEE1F-1BE6-4957-96CD-FEDB240AF704

Q38163071-16C90FE6-84F7-475E-8C9C-7FA17EF3C345

Q38163071-2593ECEC-CB2B-407D-ADB5-719537714774

Q38163071-28C94A44-60B9-4923-A4EB-AFAB725275E8

Q38163071-2B954597-61CB-4CFA-847E-C73E8385F307

Q38163071-32E59063-EC75-46DE-BDF8-90392BE31C75

Q38163071-37EFA91C-F73D-46C8-868D-C221753E46FC

Q38163071-3BAC3B46-0C15-4709-BD54-D86C8040B425

P304

Q38163071-A07C0621-D13F-42D1-9B52-9DBBE61BF8C5

P31

Q38163071-65c702bf-139a-4b82-bad1-bb74b1f00a05

Q38163071-EC06086A-A2EA-4909-8158-287D36BED0CD

P356

Q38163071-0EAAD88D-264D-4A2F-9A25-ECB7098F17F4

P433

Q38163071-DB1EBCB5-BC05-4669-8DD3-436886D995E6

P478

Q38163071-41AFC902-12F1-4DCB-90E7-C82205F3DE9C

P577

Q38163071-05824A04-1CF4-49ED-A4AF-D78E6DB526FE

P698

Q38163071-ABDE38BF-A1F2-4311-8D89-F8855F4B8329

P921

Q38163071-40372598-CD40-4F55-AF61-6E3ED0830C97

P356

P1433

Diabetes, Obesity and Metabolism

P1476

Dapagliflozin compared with ot ...... iew and network meta-analysis.

@en

P2093

A H Barnett

http://www.w3.org/2001/XMLSchema#string

G Wygant

http://www.w3.org/2001/XMLSchema#string

I Wood

http://www.w3.org/2001/XMLSchema#string

M Roudaut

http://www.w3.org/2001/XMLSchema#string

N Hawkins

http://www.w3.org/2001/XMLSchema#string

R Townsend

http://www.w3.org/2001/XMLSchema#string

S Goring

http://www.w3.org/2001/XMLSchema#string

P2860

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

Performing meta-analysis with incomplete statistical information in clinical trials

A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials.

The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus.

Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes.

Assessing the value of weight loss among primary care patients.

Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes.

Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.

Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus.

P304

433-442

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/DOM.12239

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24237939

http://www.w3.org/2001/XMLSchema#string

P921